Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

J. M. Brouwer, Philip; G. Caniels, Tom; van der Straten, Karlijn; L. Snitselaar, Jonne; Aldon, Yoann; Bangaru, Sandhya; L. Torres, Jonathan; M. A. Okba, Nisreen; Claireaux, Mathieu; Kerster, Gius; E. H. Bentlage, Arthur; M. van Haaren, Marlies; Guerra, Denise; A. Burger, Judith; E. Schermer, Edith; D. Verheul, Kirsten; van der Velde, Niels; van der Kooi, Alex; van Schooten, Jelle; J. van Breemen, Mariëlle; P. L. Bijl, Tom; Sliepen, Kwinten; Aartse, Aafke; Derking, Ronald; Bontjer, Ilja; A. Kootstra, Neeltje; Joost Wiersinga, W.; Vidarsson, Gestur; L. Haagmans, Bart; B. Ward, Andrew; J. de Bree, Godelieve; W. Sanders, Rogier; J. van Gils, Marit

doi:10.1126/science.abc5902

Public

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Shared by NobleBlocks on Aug 7, 2020 • 12:00 AM UTC

Authors:

Philip J. M. Brouwer

Tom G. Caniels

Karlijn van der Straten

Abstract

Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al. isolated 403 monoclonal antibodies from three convalescent COVID-19 patients. They s...

Discussions